Developer docs
API playgroundTry for free, no card

Search company profiles

Laboratorios Salvat

Full company profile

uuid000hbis

Namestring
Laboratorios Salvat
Legal namestring
Laboratorios Salvat, S.A.
Websiteurl
svt.com
Company typeenum
Private
Founded yearint
1955
Descriptiontext

Laboratorios Salvat is a Spanish family-owned pharmaceutical company founded in 1955, headquartered in Barcelona and operating across ENT (otolaryngology), ophthalmology, gastroenterology, urology, and consumer healthcare. It employs roughly 500 people, generates over €100M in annual revenue (2025), and sells in more than 50 countries with approximately 40% of sales generated internationally. The group owns three production facilities in Spain (Barcelona corporate and manufacturing, Pharmaloop near Madrid, and Alcalá de Henares) plus a U.S. subsidiary in Tamarac, Florida (Salvat USA, established 2006). Reported 2025 EBITDA growth of 25% coincides with a leadership transition to CEO Jordi Muntañola.

The company's competitive position rests on a proprietary technology stack rather than discovery science. Its core platform is Blow-Fill-Seal (BFS) aseptic manufacturing for sterile single-dose liquid formulations, complemented by the IMPACT-SVT nanoemulsion technology, an orally dispersible tablet platform, and the BONECURE cell therapy program developed with Histocell. Flagship brands include Cetraxal and Otovel (otic fluoroquinolones), Clotic (an antifungal for otomycosis holding an FDA Orphan Drug Designation granted in October 2025), Cristalmina (a chlorhexidine antiseptic that scaled from €3M to €9M over seven years), and Monolitum (gastroenterology). R&D intensity is reported at 15% of turnover (€10M+), and three FDA approvals have been secured across the product portfolio, with an additional FDA approval granted in October 2024 for sterile BFS drug manufacturing at the Pharmaloop site.

The business model combines three revenue streams: (1) proprietary prescription and consumer healthcare products distributed through pharmacy channels in core European and Latin American markets, (2) international licensing and distribution partnerships—WraSer/Arbor in the United States and Lee's Pharmaceutical in China (Phase III for Cetraxal)—and (3) third-party CDMO services through the Pharmaloop subsidiary, acquired in 2017 and now operating from a €65M plant with 350M units/year capacity rising to 500M units at full ramp. Pharmaloop's FDA approval (October 2024) opens U.S. contract manufacturing as a fourth strategic lever alongside the proprietary portfolio.

Short descriptiontext

Laboratorios Salvat is a Spanish family-owned pharmaceutical company founded in 1955, specializing in ENT, ophthalmology, gastroenterology, and consumer healthcare products. It manufactures sterile single-dose formulations via proprietary Blow-Fill-Seal technology and operates a CDMO business through its Pharmaloop subsidiary.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersEsplugas De Llobregat, Spain
HQ citystring
Esplugas De Llobregat
HQ countrystring
Spain
HQ regionstring
Europe
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
prescription pharmaceuticals, blow-fill-seal manufacturing, ophthalmic therapeutics, otic medications, sterile contract manufacturing
Industry4 codes
PRIMARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
SECONDARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAAKAB
Drug Product Fill-Finish & Aseptic Manufacturing Services
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Prescription Pharmaceuticals
Social media profiles3 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

Sale of proprietary pharmaceutical products across therapeutic areas including otolaryngology, ophthalmology, gastroenterology, and consumer healthcare. Products include prescription drugs and OTC consumer health products sold through pharmacies and healthcare providers.

svt.com
2International Licensing and Royalties
TypeLicensing Royalties
Description

International sales represent approximately 40% of business. Licensing agreements with regional distributors including Lee's Pharmaceutical (China), WraSer/Arbor Pharmaceuticals (US), and other licensees in Europe, Canada, Mexico, South America, Africa, Middle East, India, Southeast Asia, and South Korea.

svt.com
3CDMO Manufacturing Services
TypeProfessional Services
Description

Contract development and manufacturing organization services offered through Pharmaloop subsidiary. FDA-approved sterile liquids manufacturing for third parties with 500 million sterile vials per year capacity.

svt.com
4Consumer Healthcare Products
TypeOne Time License
Description

OTC products including Cristalmina (chlorhexidine antiseptic), Herpix, and other consumer health supplements sold through pharmacies.

svt.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Prescription pharmaceutical products
ModelOtherBilling cadenceMulti-year contract
Notes

Prescription medications sold through pharmacies and healthcare providers. Pricing regulated by national healthcare systems. Specific pricing not publicly disclosed.

svt.com
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Salvat Foundation
Description

Non-profit organization established in 1972, focused on innovation through a biannual prize for Research in Pharmaceutical Technology, and patronage of arts focusing on Music and Contemporary Art.

svt.com
Core offering1 text field

Laboratorios Salvat develops, manufactures, and commercializes prescription and consumer healthcare pharmaceutical products focused primarily on otolaryngology (ear) and ophthalmology (eye), along with gastroenterology, urology, and self-care lines. The company operates proprietary Blow-Fill-Seal (BFS) aseptic manufacturing technology for sterile single-dose formulations and runs a CDMO business through its Pharmaloop subsidiary offering contract manufacturing for third parties.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Record €100+ million revenue with 25% EBITDA growth in 2025
+4 more records
Product overview1 text field

Laboratorios Salvat is a private pharmaceutical company established in Barcelona in 1955, specializing in the development and manufacture of prescription and consumer healthcare products. The company focuses primarily on otolaryngology (ear conditions) and ophthalmology (eye conditions), with additional presence in gastroenterology, urology, and consumer self-care. Key prescription products include Cetraxal Otico and Cetraxal Plus (otology treatments with unique ciprofloxacin combinations in single-dose vials), OTOVEL (pediatric ear infection treatment), Clotic (FDA-approved otomycosis treatment with Orphan Drug Designation), and Monolitum/Monolitum Flas (lansoprazole for ulcers and reflux). The consumer healthcare portfolio centers on the flagship Cristalmina antiseptic brand (chlorhexidine-based), the Relive eye care line (hyaluronic acid-based dry eye treatments), probiotic supplements (Megalevure), and various wellness products. Salvat operates with a CDMO (Contract Development and Manufacturing Organization) division offering Blow-Fill-Seal (BFS) sterile manufacturing technology, serving both its own product portfolio and third-party clients. The company maintains manufacturing facilities in Barcelona, Madrid (Pharmaloop), and Tamarac, Florida, with products marketed across otolaryngology, ophthalmology, gastroenterology, urology, and consumer healthcare therapeutic areas.

Product and service23 records
1Cetraxal Otico
CategoryPrescription Product
Description

Ciprofloxacin otic solution for the treatment of ear infections; first topical antibiotic otic product of its kind, available in single-dose preservative-free vials using BFS technology. Sold via pharmacies and healthcare providers.

2Cetraxal Plus
CategoryPrescription Product
Description

Unique combination of ciprofloxacin and fluocinolone otic solution in single-dose preservative-free vials; first combination of its kind for ear infection treatment.

3OTOVEL
CategoryPrescription Product
Description

Combination of ciprofloxacin (fluoroquinolone antibacterial) and fluocinolone acetonide (corticosteroid) indicated for acute otitis media with tympanostomy tubes in pediatric patients aged 6 months and older. Available in single-dose 0.25 mL vials.

4Clotic
CategoryPrescription Product
Description

Clotrimazole-based treatment for otomycosis (fungal ear infections). FDA approved with Orphan Drug Designation, addressing an unmet clinical need in the management of fungal ear infections.

5Monolitum / Monolitum Flas
CategoryPrescription Product
Description

Lansoprazole orally dispersible tablet (ODT) for acute treatment of duodenal ulcers, gastric ulcers, and gastroesophageal reflux disease; leading OTC product for ulcer treatment, leveraging proprietary buccodispersible tablet technology.

6Cristalmina
CategoryConsumer Healthcare
Description

Chlorhexidine gluconate topical antiseptic available in multiple presentations (10 mg/ml drops, spray, gel, plus 20 mg/ml, and Hospital 2% aqueous solution). Spain's market-leading antiseptic and Salvat's flagship consumer brand.

7Ebernet
CategoryPrescription Product
Description

Eberconazole topical antifungal; first new chemical entity (NCE) developed by Salvat to reach market, sold across three continents.

8Herpix
CategoryConsumer Healthcare
Description

Oral food supplement for Herpes Simplex Virus management, containing lysine, Echinacea purpurea, vitamin C, and zinc.

9Relive Eye Care Line
CategoryConsumer Healthcare
Description

Eye drop line including Relive Ojos Secos (hyaluronic acid and glycerin for dry eye), Relive Noche (with carboxymethylcellulose for nighttime use), Relive Sicca (with sodium hyaluronate, triglycerides, and castor oil), and Relive Total Care (with polyvinylpyrrolidone and cyanocobalamin).

10Ilmago
CategoryPrescription Product
Description

Combination of dutasteride and tamsulosin hydrochloride for the treatment of benign prostatic hyperplasia (BPH).

11Tebarat / Tebarat 1 mg/ml
CategoryPrescription Product
Description

Azelastine ophthalmic solution for eye allergies and azelastine hydrochloride nasal spray for allergic rhinitis.

12Tanolux
CategoryPrescription Product
Description

Latanoprost ophthalmic solution for glaucoma treatment.

13Bimeox
CategoryPrescription Product
Description

Bimatoprost ophthalmic product.

14Cetraflux
CategoryPrescription Product
Description

Ciprofloxacin ophthalmic product.

15Ursitan
CategoryPrescription Product
Description

Tobramycin ophthalmic product.

16Salvacolina / Salvacolina Flas
CategoryConsumer Healthcare
Description

Loperamide product (capsules and orally dispersible tablet) for symptomatic treatment of acute nonspecific diarrhea; first major brand launched by Salvat in 1959.

17Urosens Line
CategoryConsumer Healthcare
Description

Cranberry-based consumer supplement range for urinary tract health, including Urosens, Urosens forte (with ursolic acid), Urosens intense (with D-mannose and probiotic strains), and Urosens manosa.

18Levogastrol
CategoryPrescription Product
Description

Levosulpiride product for gastrointestinal disorders.

19Megalevure Probiotic Line
CategoryConsumer Healthcare
Description

Probiotic supplements including Megalevure (with Saccharomyces boulardii, Lactobacillus rhamnosus GG, Lactobacillus helveticus, Bifidobacterium longum, FOS, and vitamin D3) and Megalevure Protransitus (with Lactobacillus Plantarum).

20Audiovit / Tinnitan Duo
CategoryConsumer Healthcare
Description

Ear health and tinnitus support supplements, including Audiovit (magnesium, Ginkgo biloba, melatonin) and Tinnitan Duo (L-tryptophan, Ginkgo biloba, magnesium, melatonin, vitamins B5/B6, zinc).

21Nasolina
CategoryConsumer Healthcare
Description

Oxymetazoline nasal decongestant.

22Pharmaloop CDMO Services
CategoryCDMO Services
Description

Contract Development and Manufacturing Organization (CDMO) services for sterile liquid pharmaceuticals, leveraging BFS technology at an FDA-approved facility with capacity of 500 million sterile vials per year. Offered to third-party pharmaceutical companies.

23IMPACT-SVT Nanoemulsion (Clobetasol)
CategoryPrescription Product
Description

Pioneering ocular corticosteroid (clobetasol) formulated in proprietary nanoemulsion for the treatment of inflammation and pain after ocular surgery, leveraging IMPACT-SVT nanoemulsion technology.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

WraSer Pharmaceuticals commercializes Otovel (ciprofloxacin + fluocinolone) otic solution in the US market. Partnership began with launch of first FDA-approved product from Salvat in US market in 2016.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Joint launch announcement with Salvat for OTOVEL in August 2016. Arbor commercializes the product in US market as the first and only antibiotic and steroid combination ear drop available in sterile, preservative-free single-dose vials.

Strategic tierStrategicTypeChannel Partner/ Reseller/ Distributor
Description

Agreement for distribution of Cetraxal Plus in China, Hong Kong, and Taiwan. Phase III clinical trial began January 2021 with 600 patients from 44 hospitals led by Fudan University researchers. Strategic market entry for Salvat in Chinese pharmaceutical market.

Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Collaboration on BONECURE project - innovative cell therapy for treatment of non-consolidated bone fractures using pre-differentiated mesenchymal stem cells. Phase II clinical trial completed with promising results.

Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Biopharmaceutical company specializing in regenerative medicine and cell therapies. Collaboration on Phase II clinical trial for bone fracture treatment conducted at Teknon Medical Center Barcelona and Hospital Universitario La Paz Madrid.

6Pharmaloop
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

Wholly-owned subsidiary acquired in 2017 in Madrid. First fully autonomous pharmaceutical production center in Spain with BFS technology. FDA-approved for US market manufacturing. Offers contract development and manufacturing services to third parties.

svt.com
Strategic tierMinorTypeGTM or Marketing Partner
Description

Japanese companies visited Pharmaloop facilities through ICEX and IcexJapon trade programs for potential business partnerships.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Consortium for development of INDREYE research project 'Innovative solutions for the treatment and diagnosis of dry eye syndrome' funded by Spanish National Program INNPACTO, co-financed by European Union ERDF/FEDER.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Privately-held Spanish pharmaceutical group with diversified specialty pharma, API manufacturing, and CDMO activities, comparable in ownership profile and breadth of pharma-plus-manufacturing model.

TypeDirect peer
Description

Spanish specialty pharmaceutical company with overlapping ENT, OTC, and consumer healthcare franchises in Iberia and Latin America, similar mid-sized revenue profile and family-influenced shareholder base.

TypeDirect peer
Description

Spanish pharma with proprietary drug delivery technologies (e.g., ISM platform) and a CDMO/manufacturing services arm, directly comparable to Salvat's combination of branded specialty pharma plus a BFS-based CDMO.

TypeDirect peer
Description

Barcelona-based mid-cap pharmaceutical company with specialties in ENT, dermatology, and sterile injectables CDMO services, overlapping Salvat in therapeutic focus, geography, and manufacturing services model.

TypeBroad incumbent
Description

Largest Spanish-listed specialty pharma, with dermatology, ENT, and gastroenterology franchises and broader European/US commercial reach — a relevant scale benchmark for Salvat's specialty pharma ambitions.

TypeBroad incumbent
Description

Global ophthalmology specialty business (part of Bausch Health) covering prescription ophthalmics, surgical, and consumer eye care — directly comparable to Salvat's ophthalmology franchise including the Relive dry-eye line and forthcoming clobetasol nanoemulsion.

7Recipharm
TypeDirect peer
Description

Global CDMO offering sterile liquid, Blow-Fill-Seal and aseptic manufacturing services to pharma customers — directly comparable to Pharmaloop's service offering and target customer base.

TypeBroad incumbent
Description

Large global CDMO with broad sterile manufacturing and Blow-Fill-Seal capacity across multiple geographies; relevant as both a competitor to Pharmaloop and a valuation benchmark for BFS-based CDMO businesses.

TypeDirect peer
Description

UK-listed specialty pharma focused on niche prescription and consumer healthcare brands distributed internationally — comparable in model of acquiring and commercializing niche specialty brands across multiple geographies.

10Laboratorios Kern Pharma
TypeRegional player
Description

Spanish generics and specialty pharma with hospital and CDMO services, overlapping Salvat in therapeutic breadth and Iberian footprint while competing in adjacent prescription and consumer segments.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles16 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Laboratorios Salvat

Prescription Pharmaceuticalssvt.com

Laboratorios Salvat is a Spanish family-owned pharmaceutical company founded in 1955, specializing in ENT, ophthalmology, gastroenterology, and consumer healthcare products. It manufactures sterile single-dose formulations via proprietary Blow-Fill-Seal technology and operates a CDMO business through its Pharmaloop subsidiary.

What Laboratorios Salvat does

Laboratorios Salvat is a Spanish family-owned pharmaceutical company founded in 1955, headquartered in Barcelona and operating across ENT (otolaryngology), ophthalmology, gastroenterology, urology, and consumer healthcare. It employs roughly 500 people, generates over €100M in annual revenue (2025), and sells in more than 50 countries with approximately 40% of sales generated internationally. The group owns three production facilities in Spain (Barcelona corporate and manufacturing, Pharmaloop near Madrid, and Alcalá de Henares) plus a U.S. subsidiary in Tamarac, Florida (Salvat USA, established 2006). Reported 2025 EBITDA growth of 25% coincides with a leadership transition to CEO Jordi Muntañola.

The company's competitive position rests on a proprietary technology stack rather than discovery science. Its core platform is Blow-Fill-Seal (BFS) aseptic manufacturing for sterile single-dose liquid formulations, complemented by the IMPACT-SVT nanoemulsion technology, an orally dispersible tablet platform, and the BONECURE cell therapy program developed with Histocell. Flagship brands include Cetraxal and Otovel (otic fluoroquinolones), Clotic (an antifungal for otomycosis holding an FDA Orphan Drug Designation granted in October 2025), Cristalmina (a chlorhexidine antiseptic that scaled from €3M to €9M over seven years), and Monolitum (gastroenterology). R&D intensity is reported at 15% of turnover (€10M+), and three FDA approvals have been secured across the product portfolio, with an additional FDA approval granted in October 2024 for sterile BFS drug manufacturing at the Pharmaloop site.

The business model combines three revenue streams: (1) proprietary prescription and consumer healthcare products distributed through pharmacy channels in core European and Latin American markets, (2) international licensing and distribution partnerships—WraSer/Arbor in the United States and Lee's Pharmaceutical in China (Phase III for Cetraxal)—and (3) third-party CDMO services through the Pharmaloop subsidiary, acquired in 2017 and now operating from a €65M plant with 350M units/year capacity rising to 500M units at full ramp. Pharmaloop's FDA approval (October 2024) opens U.S. contract manufacturing as a fourth strategic lever alongside the proprietary portfolio.

Laboratorios Salvat firmographics

Firmographics
Name
Laboratorios Salvat
Legal name
Laboratorios Salvat, S.A.
Website
https://svt.com
Company type
Private
Founded year
1955
Operating status
Operating
Headcount range
251–500 employees
Short description
Laboratorios Salvat is a Spanish family-owned pharmaceutical company founded in 1955, specializing in ENT, ophthalmology, gastroenterology, and consumer healthcare products. It manufactures sterile single-dose formulations via proprietary Blow-Fill-Seal technology and operates a CDMO business through its Pharmaloop subsidiary.
Ownership category
akta.pro rank

Laboratorios Salvat industry classification

Industry
Product category
Prescription Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
SECONDARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAAKAB
Drug Product Fill-Finish & Aseptic Manufacturing Services

Keywords

  • Prescription pharmaceuticals
  • Blow-fill-seal manufacturing
  • Ophthalmic therapeutics
  • Otic medications
  • Sterile contract manufacturing

Where Laboratorios Salvat is headquartered

Location

Headquarters

HQ city
Esplugas De Llobregat
HQ country
Spain
HQ region
Europe

Offices6 records

Markets served

Laboratorios Salvat business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical Product Sales: Sale of proprietary pharmaceutical products across therapeutic areas including otolaryngology, ophthalmology, gastroenterology, and consumer healthcare. Products include prescription drugs and OTC consumer health products sold through pharmacies and healthcare providers.
  2. International Licensing and Royalties: International sales represent approximately 40% of business. Licensing agreements with regional distributors including Lee's Pharmaceutical (China), WraSer/Arbor Pharmaceuticals (US), and other licensees in Europe, Canada, Mexico, South America, Africa, Middle East, India, Southeast Asia, and South Korea.
  3. CDMO Manufacturing Services: Contract development and manufacturing organization services offered through Pharmaloop subsidiary. FDA-approved sterile liquids manufacturing for third parties with 500 million sterile vials per year capacity.
  4. Consumer Healthcare Products: OTC products including Cristalmina (chlorhexidine antiseptic), Herpix, and other consumer health supplements sold through pharmacies.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractPrescription pharmaceutical products

Go-to-market motion3 records

Distribution channels6 records

Marketing channels5 records

Laboratorios Salvat product offering

Product offering

Core offering

Laboratorios Salvat develops, manufactures, and commercializes prescription and consumer healthcare pharmaceutical products focused primarily on otolaryngology (ear) and ophthalmology (eye), along with gastroenterology, urology, and self-care lines. The company operates proprietary Blow-Fill-Seal (BFS) aseptic manufacturing technology for sterile single-dose formulations and runs a CDMO business through its Pharmaloop subsidiary offering contract manufacturing for third parties.

Product overview

Laboratorios Salvat is a private pharmaceutical company established in Barcelona in 1955, specializing in the development and manufacture of prescription and consumer healthcare products. The company focuses primarily on otolaryngology (ear conditions) and ophthalmology (eye conditions), with additional presence in gastroenterology, urology, and consumer self-care. Key prescription products include Cetraxal Otico and Cetraxal Plus (otology treatments with unique ciprofloxacin combinations in single-dose vials), OTOVEL (pediatric ear infection treatment), Clotic (FDA-approved otomycosis treatment with Orphan Drug Designation), and Monolitum/Monolitum Flas (lansoprazole for ulcers and reflux). The consumer healthcare portfolio centers on the flagship Cristalmina antiseptic brand (chlorhexidine-based), the Relive eye care line (hyaluronic acid-based dry eye treatments), probiotic supplements (Megalevure), and various wellness products. Salvat operates with a CDMO (Contract Development and Manufacturing Organization) division offering Blow-Fill-Seal (BFS) sterile manufacturing technology, serving both its own product portfolio and third-party clients. The company maintains manufacturing facilities in Barcelona, Madrid (Pharmaloop), and Tamarac, Florida, with products marketed across otolaryngology, ophthalmology, gastroenterology, urology, and consumer healthcare therapeutic areas.

Differentiator

Problem solved

Functional benefit

Brands

  • Salvat Foundation: Non-profit organization established in 1972, focused on innovation through a biannual prize for Research in Pharmaceutical Technology, and patronage of arts focusing on Music and Contemporary Art.

Products and services

  • Cetraxal Otico Ciprofloxacin otic solution for the treatment of ear infections; first topical antibiotic otic product of its kind, available in single-dose preservative-free vials using BFS technology. Sold via pharmacies and healthcare providers.
  • Cetraxal Plus Unique combination of ciprofloxacin and fluocinolone otic solution in single-dose preservative-free vials; first combination of its kind for ear infection treatment.
  • OTOVEL Combination of ciprofloxacin (fluoroquinolone antibacterial) and fluocinolone acetonide (corticosteroid) indicated for acute otitis media with tympanostomy tubes in pediatric patients aged 6 months and older. Available in single-dose 0.25 mL vials.
  • Clotic Clotrimazole-based treatment for otomycosis (fungal ear infections). FDA approved with Orphan Drug Designation, addressing an unmet clinical need in the management of fungal ear infections.
  • Monolitum / Monolitum Flas Lansoprazole orally dispersible tablet (ODT) for acute treatment of duodenal ulcers, gastric ulcers, and gastroesophageal reflux disease; leading OTC product for ulcer treatment, leveraging proprietary buccodispersible tablet technology.
  • Cristalmina Chlorhexidine gluconate topical antiseptic available in multiple presentations (10 mg/ml drops, spray, gel, plus 20 mg/ml, and Hospital 2% aqueous solution). Spain's market-leading antiseptic and Salvat's flagship consumer brand.
  • Ebernet Eberconazole topical antifungal; first new chemical entity (NCE) developed by Salvat to reach market, sold across three continents.
  • Herpix Oral food supplement for Herpes Simplex Virus management, containing lysine, Echinacea purpurea, vitamin C, and zinc.
  • Relive Eye Care Line Eye drop line including Relive Ojos Secos (hyaluronic acid and glycerin for dry eye), Relive Noche (with carboxymethylcellulose for nighttime use), Relive Sicca (with sodium hyaluronate, triglycerides, and castor oil), and Relive Total Care (with polyvinylpyrrolidone and cyanocobalamin).
  • Ilmago Combination of dutasteride and tamsulosin hydrochloride for the treatment of benign prostatic hyperplasia (BPH).
  • Tebarat / Tebarat 1 mg/ml Azelastine ophthalmic solution for eye allergies and azelastine hydrochloride nasal spray for allergic rhinitis.
  • Tanolux Latanoprost ophthalmic solution for glaucoma treatment.
  • Bimeox Bimatoprost ophthalmic product.
  • Cetraflux Ciprofloxacin ophthalmic product.
  • Ursitan Tobramycin ophthalmic product.
  • Salvacolina / Salvacolina Flas Loperamide product (capsules and orally dispersible tablet) for symptomatic treatment of acute nonspecific diarrhea; first major brand launched by Salvat in 1959.
  • Urosens Line Cranberry-based consumer supplement range for urinary tract health, including Urosens, Urosens forte (with ursolic acid), Urosens intense (with D-mannose and probiotic strains), and Urosens manosa.
  • Levogastrol Levosulpiride product for gastrointestinal disorders.
  • Megalevure Probiotic Line Probiotic supplements including Megalevure (with Saccharomyces boulardii, Lactobacillus rhamnosus GG, Lactobacillus helveticus, Bifidobacterium longum, FOS, and vitamin D3) and Megalevure Protransitus (with Lactobacillus Plantarum).
  • Audiovit / Tinnitan Duo Ear health and tinnitus support supplements, including Audiovit (magnesium, Ginkgo biloba, melatonin) and Tinnitan Duo (L-tryptophan, Ginkgo biloba, magnesium, melatonin, vitamins B5/B6, zinc).
  • Nasolina Oxymetazoline nasal decongestant.
  • Pharmaloop CDMO Services Contract Development and Manufacturing Organization (CDMO) services for sterile liquid pharmaceuticals, leveraging BFS technology at an FDA-approved facility with capacity of 500 million sterile vials per year. Offered to third-party pharmaceutical companies.
  • IMPACT-SVT Nanoemulsion (Clobetasol) Pioneering ocular corticosteroid (clobetasol) formulated in proprietary nanoemulsion for the treatment of inflammation and pain after ocular surgery, leveraging IMPACT-SVT nanoemulsion technology.

Quantifiable outcome

  • Record €100+ million revenue with 25% EBITDA growth in 2025
  • +4 more outcomes

Companies that use Laboratorios Salvat

Customer profile

Named customers4 records

Segments6 records

Ideal customer profiles4 records

Laboratorios Salvat technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Laboratorios Salvat partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core, strategic and minor.

  • WraSer PharmaceuticalscoreChannel Partner/ Reseller/ DistributorWraSer Pharmaceuticals commercializes Otovel (ciprofloxacin + fluocinolone) otic solution in the US market. Partnership began with launch of first FDA-approved product from Salvat in US market in 2016.
  • Arbor Pharmaceuticals, LLCcoreChannel Partner/ Reseller/ DistributorJoint launch announcement with Salvat for OTOVEL in August 2016. Arbor commercializes the product in US market as the first and only antibiotic and steroid combination ear drop available in sterile, preservative-free single-dose vials.
  • Lee's PharmaceuticalstrategicChannel Partner/ Reseller/ DistributorAgreement for distribution of Cetraxal Plus in China, Hong Kong, and Taiwan. Phase III clinical trial began January 2021 with 600 patients from 44 hospitals led by Fudan University researchers. Strategic market entry for Salvat in Chinese pharmaceutical market.
  • HistocellstrategicStrategic or Co-development PartnerCollaboration on BONECURE project - innovative cell therapy for treatment of non-consolidated bone fractures using pre-differentiated mesenchymal stem cells. Phase II clinical trial completed with promising results.
  • Histocell (BONECURE)strategicStrategic or Co-development PartnerBiopharmaceutical company specializing in regenerative medicine and cell therapies. Collaboration on Phase II clinical trial for bone fracture treatment conducted at Teknon Medical Center Barcelona and Hospital Universitario La Paz Madrid.
  • PharmaloopcoreOEM/ Whitelabel/ Licensing PartnerWholly-owned subsidiary acquired in 2017 in Madrid. First fully autonomous pharmaceutical production center in Spain with BFS technology. FDA-approved for US market manufacturing. Offers contract development and manufacturing services to third parties.
  • ICE JacexminorGTM or Marketing PartnerJapanese companies visited Pharmaloop facilities through ICEX and IcexJapon trade programs for potential business partnerships.
  • INDREYE ConsortiumminorStrategic or Co-development PartnerConsortium for development of INDREYE research project 'Innovative solutions for the treatment and diagnosis of dry eye syndrome' funded by Spanish National Program INNPACTO, co-financed by European Union ERDF/FEDER.

Scale indicators10 records

Recent moves9 records

Expansion highlights7 records

Laboratorios Salvat competitors and assessment

Company assessment

Broad incumbents

  • Esteve: Privately-held Spanish pharmaceutical group with diversified specialty pharma, API manufacturing, and CDMO activities, comparable in ownership profile and breadth of pharma-plus-manufacturing model.
  • Almirall: Largest Spanish-listed specialty pharma, with dermatology, ENT, and gastroenterology franchises and broader European/US commercial reach — a relevant scale benchmark for Salvat's specialty pharma ambitions.
  • Bausch + Lomb: Global ophthalmology specialty business (part of Bausch Health) covering prescription ophthalmics, surgical, and consumer eye care — directly comparable to Salvat's ophthalmology franchise including the Relive dry-eye line and forthcoming clobetasol nanoemulsion.
  • Catalent: Large global CDMO with broad sterile manufacturing and Blow-Fill-Seal capacity across multiple geographies; relevant as both a competitor to Pharmaloop and a valuation benchmark for BFS-based CDMO businesses.

Direct peers

  • Faes Farma: Spanish specialty pharmaceutical company with overlapping ENT, OTC, and consumer healthcare franchises in Iberia and Latin America, similar mid-sized revenue profile and family-influenced shareholder base.
  • Laboratorios Rovi: Spanish pharma with proprietary drug delivery technologies (e.g., ISM platform) and a CDMO/manufacturing services arm, directly comparable to Salvat's combination of branded specialty pharma plus a BFS-based CDMO.
  • Reig Jofre: Barcelona-based mid-cap pharmaceutical company with specialties in ENT, dermatology, and sterile injectables CDMO services, overlapping Salvat in therapeutic focus, geography, and manufacturing services model.
  • Recipharm: Global CDMO offering sterile liquid, Blow-Fill-Seal and aseptic manufacturing services to pharma customers — directly comparable to Pharmaloop's service offering and target customer base.
  • Alliance Pharma: UK-listed specialty pharma focused on niche prescription and consumer healthcare brands distributed internationally — comparable in model of acquiring and commercializing niche specialty brands across multiple geographies.

Regional players

  • Laboratorios Kern Pharma: Spanish generics and specialty pharma with hospital and CDMO services, overlapping Salvat in therapeutic breadth and Iberian footprint while competing in adjacent prescription and consumer segments.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Laboratorios Salvat social profiles

Digital presence

Laboratorios Salvat compliance and trust

Trust signal

Compliance4 records

Laboratorios Salvat financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Laboratorios Salvat leadership team

Management profile

Number of profiles

Profiles16 records

Laboratorios Salvat subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Laboratorios Salvat funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Laboratorios Salvat M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Laboratorios Salvat

What does Laboratorios Salvat do?

Laboratorios Salvat develops, manufactures, and commercializes prescription and consumer healthcare pharmaceutical products focused primarily on otolaryngology (ear) and ophthalmology (eye), along with gastroenterology, urology, and self-care lines. The company operates proprietary Blow-Fill-Seal (BFS) aseptic manufacturing technology for sterile single-dose formulations and runs a CDMO business through its Pharmaloop subsidiary offering contract manufacturing for third parties.

Is Laboratorios Salvat a public or private company?

Laboratorios Salvat is a private company. It is classified as family owned and is currently operating.

When was Laboratorios Salvat founded?

Laboratorios Salvat was founded in 1955. It employs 251 to 500 people.

Where is Laboratorios Salvat based?

Laboratorios Salvat is headquartered in Esplugas De Llobregat, Spain, in the Europe region.

How does Laboratorios Salvat make money?

Four revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are international Licensing and Royalties, CDMO Manufacturing Services and consumer Healthcare Products.

Who are Laboratorios Salvat's main competitors?

Broad incumbents on record are Esteve, Almirall, Bausch + Lomb and Catalent. Direct peers are Faes Farma, Laboratorios Rovi, Reig Jofre, Recipharm and Alliance Pharma. Laboratorios Kern Pharma is listed as a regional player.

Does Laboratorios Salvat have an API?

No public API is recorded for Laboratorios Salvat.

What industry is Laboratorios Salvat in?

Laboratorios Salvat's product category is Prescription Pharmaceuticals. Its primary akta.pro industry code is HLAIACAK, Ophthalmology Specialty Pharmaceuticals, with a secondary code of HLAGABAH, Sterile Fill-Finish & Aseptic Manufacturing CDMO. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EXPANSIONSalvat pone en marcha Pharmaloop para apoyar su crecimiento en EEUUSalvat, a Peris family-owned pharmaceutical, acquired a Sigma Tau plant in Alcalá de Henares, now operating as Pharmaloop, to boost industrial capacity for its US expansion. The acquisition aims to meet production needs for its international growth plans.PR NewswireLaboratorios SALVAT S.A. und Arbor Pharmaceuticals LLC kündigen die Einführung der Ohrenlösung OTOVEL® (Ciprofloxacin 0,3 % und Fluocinolonacetonid 0,025 %) anLaboratorios SALVAT S.A. and Arbor Pharmaceuticals LLC announced the launch of OTOVEL, a prescription ear drop combination of ciprofloxacin and fluocinolone acetonide, in the United States. The product is marketed exclusively by Arbor in the US under a partnership with Salvat, which holds the rights to the drug. This introduction marks a significant milestone for Salvat's expansion in the US pediatric market following FDA approval.PR NewswireLaboratorios SALVAT S.A. et Arbor Pharmaceuticals, LLC annoncent le lancement de la solution otique OTOVEL® (ciprofloxacine 0,3 % et acétonide de fluocinolone 0,025 %)Laboratorios SALVAT S.A. and Arbor Pharmaceuticals, LLC jointly announced on August 31, 2016 the launch of OTOVEL® ear drops in the United States, a combination antibiotic-steroid solution that is the first and only of its kind in single-dose, sterile, preservative-free packaging. The product is indicated for acute otitis media in pediatric patients with tympanostomy tubes and was approved by the FDA in April 2016. This launch represents a significant milestone for Salvat in expanding its commercial presence in the US market, with Arbor serving as the exclusive distributor leveraging its pediatric sales force of over 200 professionals.PR NewswireLaboratorios SALVAT y Arbor Pharmaceuticals anuncian el lanzamiento de OTOVEL® solución óticaLaboratorios SALVAT and Arbor Pharmaceuticals announced the joint launch of OTOVEL® ear drops in the United States on August 31, 2016. OTOVEL is the first and only ear drop solution combining the antibiotic ciprofloxacin 0.3% with the steroid fluocinolone acetonide 0.025% in sterile, preservative-free single-dose vials, indicated for acute otitis media with tympanostomy tubes in pediatric patients. SALVAT owns the product and granted Arbor exclusive distribution rights in the US market, with FDA approval having been received in April 2016.PR NewswireLaboratorios SALVAT S.A. and Arbor Pharmaceuticals, LLC Announce the Launch of OTOVEL® (ciprofloxacin 0.3 % and fluocinolone acetonide 0.025 %) otic solutionLaboratorios SALVAT S.A. and Arbor Pharmaceuticals, LLC announced the U.S. launch of OTOVEL®, a preservative-free otic solution for treating acute otitis media with tympanostomy tubes in pediatric patients. Arbor Pharmaceuticals serves as the exclusive distributor for the product, which is owned by Laboratorios SALVAT. This launch marks a strategic expansion of Salvat's presence in the U.S. market.PR NewswireLaboratorios SALVAT S.A. and Arbor Pharmaceuticals, LLC Announce the Launch of OTOVEL® (ciprofloxacin 0.3 % and fluocinolone acetonide 0.025 %) otic solutionLaboratorios SALVAT S.A. and Arbor Pharmaceuticals, LLC announced the launch of OTOVEL®, an antibiotic and steroid combination ear drop solution, on August 29, 2016. OTOVEL® is the first product of its kind in single-dose vials and is indicated for treating acute otitis media with tympanostomy tubes in pediatric patients. The launch is a significant milestone for SALVAT as it expands its presence in the U.S. market through its partnership with Arbor, which will exclusively distribute the product.GlobeNewswirePediapharm Inc. and Laboratorios SALVAT S.A. Enter Into a License and Supply Agreement for a Novel Patented Combination Product Developed to Efficiently Treat Ear InfectionsPediapharm and SALVAT signed an agreement granting Pediapharm exclusive Canadian rights to a patented ciprofloxacin and fluocinolone otic solution for ear infections. The product targets acute otitis media with tympanostomy tubes and swimmer's ear, with Health Canada registration planned for 2015 and launch by end of 2016.